

Accepted Manuscript



Effect of Allopurinol on Cardiovascular Outcomes in Hyperuricemic patients A Cohort Study

Kasper Søltoft Larsen, MD, PhD, Anton Pottegård, M.Sc. Pharm, PhD, Hanne M. Lindegaard, MD, PhD, Jesper Hallas, MD, PhD

PII: S0002-9343(15)01047-5

DOI: [10.1016/j.amjmed.2015.11.003](https://doi.org/10.1016/j.amjmed.2015.11.003)

Reference: AJM 13256

To appear in: *The American Journal of Medicine*

Received Date: 20 April 2015

Revised Date: 1 November 2015

Accepted Date: 3 November 2015

Please cite this article as: Larsen KS, Pottegård A, Lindegaard HM, Hallas J, Effect of Allopurinol on Cardiovascular Outcomes in Hyperuricemic patients A Cohort Study, *The American Journal of Medicine* (2015), doi: 10.1016/j.amjmed.2015.11.003.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Effect of Allopurinol on Cardiovascular Outcomes in Hyperuricemic patients**A Cohort Study**

Running head: Allopurinol and Cardiovascular Outcomes

Kasper Søltoft Larsen^{a,b,c}, MD, PhD; Anton Pottegård^b, M.Sc. Pharm, PhD; Hanne M Lindegaard^c, MD, PhD; Jesper Hallas^{a,b}, MD, PhD

- a) Department of Clinical Chemistry & Pharmacology, Odense University Hospital, DK-5000 Odense C.
- b) Clinical Pharmacology, Institute of Public Health, University of Southern Denmark, DK-5000 Odense C.
- c) Department of Rheumatology, Odense University Hospital, DK-5000 Odense C.

All authors had access to the data used in this study and have contributed equally to the conception and design of this study, revised the manuscript for important intellectual content and approved the final version.

Funding: none.

Conflicts of interest: All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf and declare: no support from any organization for the submitted work; Kasper Søltoft Larsen and Jesper Hallas has participated in research projects funded by Menarini, with grants paid to institutions where they have been employed and received personal fees; Jesper Hallas have participated in research projects funded by Nycomed/Takeda and personal fees for teaching; Hanne M Lindegaard has received honoraria and/or participated in research projects funded by Berlin-Chemie/Menarini, Eli Lilly, MSD, Roche and Pfizer, no other relationships or activities that could appear to have influenced the submitted work.

Keywords: Allopurinol; hyperuricemia; cardiovascular outcomes; gout.

Correspondence to: Kasper Søltoft Larsen, kaslarsen@health.sdu.dk

Download English Version:

<https://daneshyari.com/en/article/5876040>

Download Persian Version:

<https://daneshyari.com/article/5876040>

[Daneshyari.com](https://daneshyari.com)